Opinionated, data-backed coverage across all asset classes

EOG shares fell 5.5% since a Hold rating; now an analyst upgrades to Buy at 5.5x EBITDA. The upgrade hinges on crude staying above the $55-60 level built into the stock.

Spruce Biosciences (SPRB) is a small-cap biotech with a late-stage enzyme replacement therapy for MPS IIIB. The upcoming data readout creates a binary risk for the stock.

Beijing's discussions to restrict overseas access to Chinese AI models could disrupt oracle networks and DeFi protocols that depend on affordable inference.